NRC Health NRC R2K
NRC Health provides analytics and insights to measure and improve patient and employee experience for healthcare organizations in the United States. The company offers market experience solutions, a subscription-based services for improved tracking of awareness, perception, and consistency of healthcare brands; assessment of differentiators; and segmentation tools to evaluate the needs, wants, and behaviors of communities through assessments. It also provides patient experience solutions, a cross-continuum multi-mode digital platform that collects and measures data to improve patient experience, engagement, and loyalty; employee experience solutions, which combines health care with technology comprising engagement, pulse, lifecycle, culture of safety, and magnet RN satisfaction; and consumer experience solution that offers online reputation solutions, community insights, and cross-journey listening through nGage. In addition, the company offers Huey, an AI engine built for Human Understanding that serves as a healthcare experience management companion; and governance solutions provided through national conferences, publications, advisory services, and an online portal for not-for-profit health system boards of directors, executives, and physician leadership. Further, it provides patient experience, service recovery, care transitions, employee engagement, reputation management, rounding, and brand loyalty. The company was formerly known as National Research Corporation and changed its name to NRC Health April 2026. The company was founded in 1981 and is headquartered in Lincoln, Nebraska.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Strong return on equity of 41.9%.
- Healthy ROCE of 23.0%.
- Attractive dividend yield of 3.07%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -3.2% CAGR over 5 years.
- Earnings shrank at -28.5% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NRC NRC Health R2K | 19.53 | 47.63 | $440.14M | 3.07% | 23.01% | 41.86% | -3.22% | -28.55% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 31.48M | 31.41M | 32.47M | 33.86M | 31.17M | 33.48M | 35.46M | 36.42M | 37.77M | 38.44M | 37.29M | 37.69M | 36.47M | 36.16M | 37.95M | 35.31M | 35.02M | 35.82M | 33.55M | 34.04M | 34.61M | 35.19M | 34.80M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 13.06M | 12.97M | 12.40M | 13.94M | 13.65M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.49M | 21.06M | 22.20M | 21.26M | 21.16M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.90M | 19.48M | 14.47M | 16.59M | 15.59M |
| Operating Income | 5.53M | 6.03M | 8.40M | 6.32M | 7.16M | 5.83M | 6.36M | 6.55M | 8.01M | 7.02M | 7.34M | 9.98M | 8.45M | 7.12M | 8.96M | 7.76M | 9.17M | 10.70M | 10.15M | 10.22M | 11.19M | 9.28M | 12.02M | 12.02M | 12.24M | 13.14M | 11.70M | 11.50M | 11.11M | 9.02M | 9.37M | 9.96M | 8.76M | 8.87M | 7.98M | 8.60M | 1.59M | 7.74M | 4.67M | 5.57M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.16M | 3.35M | 9.93M | 6.78M | 7.80M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 899.00K | 1.03M | 1.46M | 1.37M | 1.25M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.72M | 581.00K | 6.27M | 3.27M | 4.38M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.94M | 687.00K | 2.15M | 1.47M | 1.16M |
| Net Income | 3.43M | 3.81M | 5.45M | 4.05M | 4.55M | 3.48M | 4.06M | 4.14M | 5.51M | 4.56M | 4.73M | 6.52M | 5.75M | 4.15M | 7.31M | 7.95M | 6.99M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.79M | -106.00K | 4.12M | 1.80M | 3.22M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.32 | 0.29 | 0.31 | 0.46 | 0.30 | 0.37 | 0.36 | 0.35 | 0.38 | 0.34 | 0.33 | 0.33 | 0.28 | 0.29 | 0.32 | 0.27 | 0.26 | 0.24 | 0.25 | -0.01 | 0.18 | 0.08 | 0.14 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 117.56M | 119.69M | 127.98M | 133.28M | - | 151.57M | 148.58M | 143.06M | 137.39M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 57.05M | 56.02M | 56.93M | 52.37M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | 94.52M | 92.56M | 86.13M | 85.02M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 47.98M | 52.52M | 50.93M | 62.43M |
| Operating Income | 13.70M | 13.86M | 18.73M | 22.72M | 24.81M | 28.30M | 26.45M | 31.20M | 34.22M | 35.27M | 43.03M | 42.68M | - | 46.54M | 40.05M | 35.19M | 22.59M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | 49.30M | 46.72M | 41.31M | 30.23M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.21M | 862.00K | 2.60M | 4.76M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | 42.81M | 39.96M | 32.69M | 17.84M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.02M | 8.99M | 7.91M | 6.25M |
| Net Income | 8.49M | 11.56M | 11.56M | 15.07M | 15.48M | 18.16M | 17.61M | 20.52M | 22.94M | 30.05M | - | - | - | 31.80M | 30.97M | 24.78M | 11.60M |
| Diluted EPS | 1.26 | 1.26 | 1.69 | 2.17 | - | - | - | - | - | - | 1.26 | 1.45 | - | 1.27 | 1.25 | 1.04 | 0.50 |
Compounded Sales Growth
| 5 Years: | -3.22% |
| 1 Year: | 3.70% |
Compounded Profit Growth
| 5 Years: | -28.55% |
| 1 Year: | -44.00% |
Stock Price Performance
| 1 Year: | +49.54% |
| 6 Months: | +10.32% |
| 3 Months: | +46.98% |
| 1 Month: | +18.08% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 95.77M | 100.68M | 100.05M | 111.09M | 129.51M | 128.05M | 120.62M | 127.32M | 108.03M | 110.69M | 133.42M | - | 130.46M | 122.44M | 132.54M | 134.88M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 43.72M | 24.36M | 19.60M | 20.21M |
| Cash & Equivalents | 1.11M | 2.51M | 3.52M | 8.08M | 8.29M | 22.09M | 40.04M | 42.15M | 33.02M | 34.73M | 12.99M | 13.52M | 34.69M | - | 25.03M | 6.65M | 4.23M | 4.14M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.46M | 12.38M | 11.05M | 11.11M |
| Total Liabilities | - | - | 47.19M | 45.12M | 43.30M | 39.33M | 41.76M | 53.83M | 37.82M | 37.27M | 88.95M | 77.79M | 69.11M | - | 58.43M | 73.48M | 101.25M | 120.89M |
| Current Liabilities | - | - | 26.15M | 24.40M | 35.30M | 23.78M | 27.93M | 44.17M | 31.51M | 32.31M | 47.11M | 38.16M | 31.68M | - | 33.42M | 36.20M | 35.86M | 36.62M |
| Long Term Debt | - | - | - | - | - | 8.07M | 5.74M | 3.34M | 857.00K | - | 34.18M | 29.80M | 26.55M | - | 17.69M | 29.47M | 57.90M | 75.02M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 22.18M | 36.68M | 62.68M | 79.03M |
| Total Equity | 38.60M | 44.17M | 48.58M | 55.55M | 56.74M | 71.75M | 87.75M | 74.22M | 82.81M | 90.04M | 19.08M | 32.89M | 64.31M | - | 72.03M | 48.95M | 31.28M | 13.99M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 30.92M | 31.00M | 31.07M | 31.97M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 13.67M | 14.60M | 18.48M | 19.13M | 19.32M | 26.20M | 21.89M | 26.84M | 28.09M | 39.85M | 40.92M | 40.64M | - | 36.27M | 38.11M | 34.62M | 26.45M |
| Investing Cash Flow | -3.00M | -16.98M | -6.93M | -2.35M | -2.19M | -5.72M | -1.33M | -3.75M | -6.12M | -5.97M | -4.66M | -3.72M | - | -9.84M | -15.78M | -20.28M | -10.71M |
| Financing Cash Flow | -9.55M | 3.25M | -6.89M | -16.69M | -2.82M | -1.73M | -16.87M | -32.50M | -21.12M | -54.50M | -36.35M | -15.50M | - | -55.58M | -40.71M | -16.76M | -15.84M |
| Capital Expenditure | -2.91M | -1.54M | -2.81M | -2.35M | -2.19M | -2.49M | -2.94M | -3.97M | -4.57M | -5.97M | -4.66M | -3.98M | - | -9.84M | -15.78M | -15.45M | -10.71M |
| Free Cash Flow | 10.76M | 13.06M | 15.67M | 16.78M | 17.13M | 23.70M | 18.95M | 22.87M | 23.52M | 33.88M | 36.26M | 36.65M | - | 26.43M | 22.33M | 19.18M | 15.74M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | -29.15M | -18.37M | -2.42M | -94.00K |
| Share Buybacks | 84.00K | 399.00K | - | - | - | - | 1.67M | - | - | - | - | - | 4.14M | 27.62M | 19.10M | 30.95M | 20.18M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | 62.4% | 62.3% | 60.2% | 61.9% |
| Operating Margin % | - | - | - | - | - | - | - | - | 29.1% | 29.5% | 33.6% | 32.0% | - | 30.7% | 27.0% | 24.6% | 16.4% |
| Net Margin % | - | - | - | - | - | - | - | - | 19.5% | 25.1% | - | - | - | 21.0% | 20.8% | 17.3% | 8.4% |
| ROE % | 19.2% | 23.8% | 20.8% | 26.6% | 21.6% | 20.7% | 23.7% | 24.8% | 25.5% | 157.5% | - | - | - | 44.1% | 63.3% | 79.2% | 82.9% |
| ROCE % | - | 19.9% | 24.6% | 35.1% | 28.4% | 27.9% | 31.5% | 35.0% | 36.0% | 57.9% | 59.3% | 41.9% | - | 48.0% | 46.4% | 36.4% | 23.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Kayne Anderson Rudnick Investment Management LLC | 11.70% | 2.64M | $51.49M |
| 2 | Morgan Stanley | 4.45% | 1.00M | $19.57M |
| 3 | Blackrock Inc. | 4.33% | 975.86K | $19.06M |
| 4 | Vanguard Capital Management LLC | 2.94% | 662.84K | $12.95M |
| 5 | Dimensional Fund Advisors LP | 2.17% | 489.74K | $9.56M |
| 6 | Geode Capital Management, LLC | 1.75% | 393.85K | $7.69M |
| 7 | QV Investors Inc. | 1.69% | 381.31K | $7.45M |
| 8 | Renaissance Technologies, LLC | 1.51% | 340.78K | $6.66M |
| 9 | State Street Corporation | 1.33% | 300.75K | $5.87M |
| 10 | Hotchkis & Wiley Capital Management, LLC | 1.27% | 286.84K | $5.60M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NRC